3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Solid Tumor
1
Interventions
Injections
12
pembrolizumab
11
Nivolumab
9
Paclitaxel
8
senaparib
7
Docetaxel
7
Cisplatin
6
Capecitabine
6
Gemcitabine
5
toripalimab
4
tislelizumab
4
atezolizumab
4
Ipilimumab
4
Carboplatin
4
Bevacizumab
4
sintilimab
3
Rifampin
3
Oxaliplatin
3
Itraconazole
3
130-nm albumin-bound paclitaxel
3
zimberelimab
2
pertuzumab
2
osimertinib
2
ontuxizumab
2
navoximod
2
magrolimab
2
fluzoparib
2
famitinib
2
durvalumab
2
camrelizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Solid Tumor
×
MK-4166
×
Clear all
NCT02132754
2021-01-28
MK-4166-001
Merck Sharp & Dohme LLC
Phase 1
Completed
116 enrolled
61 charts